Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Bioorg Med Chem Lett. 2011 Feb 28;21(7):2007–2010. doi: 10.1016/j.bmcl.2011.02.020

Fluorescent Water Soluble Polymers for Isozyme-Selective Interactions with Matrix Metalloproteinase-9

Rinku Dutta a, Michael D Scott a, Manas K Haldar a, Bratati Ganguly b, D K Srivastava b, Daniel L Friesner c, Sanku Mallik a,*
PMCID: PMC3063395  NIHMSID: NIHMS273786  PMID: 21367603

Abstract

Matrix metalloproteinases (MMPs) are overexpressed in various pathological conditions, including various cancers. Although these isozymes have similar active sites, the patterns of exposed amino acids on their surfaces are different. Herein, we report the synthesis and molecular interactions of two water-soluble, fluorescent polymers which demonstrate selective interactions with MMP-9 compared to MMP-7 and -10.

Keywords: Polymers, Matrix metalloproteinases, Enzymes, Selective interactions, Fluorescence spectroscopy


Water soluble, flexible polymers have been used by various groups to selectively bind to different proteins.13 The flexibility of the polymer backbone aids in the formation of multiple, complementary interaction sites between the polymer and the amino acid residues on the protein surface. These polymers have been demonstrated to be useful as affinity membranes, as switches to “turn on” enzyme activity, as selective protein immobilization agents, as protein sensors etc.13 However, the proteins used in these selective recognition experiments are structurally very different (e.g., lysozyme, bovine serum albumin, cytochrome c, etc.). To the best of our knowledge, selective binding of polymers to different isozymes of an enzyme family has not been demonstrated.

Matrix metalloproteinases (MMPs) are a group of Zn2+ containing metalloenzymes capable of hydrolyzing the extracellular matrix.4,5 These enzymes are involved in a number of different physiological processes, e.g., cell proliferation, apoptosis, differentiation, angiogenesis, chemokine/cytokine activation and the expression levels of these enzymes are strictly regulated at multiple levels.69 Various MMP isozymes (in particular MMP-9) have been shown to be upregulated in degenerative diseases, e.g., arthritis, multiple sclerosis, metastatic cancers etc.911 In healthy individuals, the serum concentration of MMP-9 is about 5 – 10 nM.12 For lung cancer patients, the concentration of this enzyme can be as high as 100 – 200 nM in the bronchial lavage fluids.13 The levels of MMP-9 serve as diagnostic and prognostic markers for these diseases.12,13

Since isozymes catalyze the same chemical reaction, their active sites are remarkably similar.14 However, the pattern of amino acid residues on the surface of the isozymes are not under evolutionary pressure and are usually not conserved.15 We reasoned that this difference can be exploited for selective binding of polymers to one isozyme in preference to the others. Herein, we report our results on selective binding to recombinant human matrix metalloproteinase-9 (MMP-9) by a set of water soluble, flexible polymers.

We synthesized two sets of monomers using two different polymerizable moieties. The first set included the use of a commonly-used water soluble compound methacrylic acid. For the second set, we choose to examine the effects of a benzene ring incorporated into the structure and 4-vinylbenzoic acid was used. We conjugated the polymerizable moieties to an alcohol (for increased water solublity and hydrogen bonding with amino acid residues on the surface of MMPs), to the fluorogenic dansyl group and to a non-selective MMP inhibitor. Different amino acids such as lysine (positively charged), aspartic acid (negatively charged) and β-alanine (non-polar) were also linked to the polymerizable groups to impart electrostatic and hydrophobic properties to the polymers (Scheme 1, synthetic details are provided in Supplementary Material).

Scheme 1.

Scheme 1

Synthesis of methacrylamide and 4-vinylbenzamide based monomers.

Random copolymers were prepared from these synthesized monomers using azoisobutyronitrile (AIBN) as the free-radical initiator following a literature protocol.2,3 Because of flexibility, we decided to prepare a small set of polymers and screen for selective interactions with MMP-9. We systemically varied the starting monomer compositions (Table 1) and studied the interactions of the resultant polymers with recombinant human MMP-7, -9 and -10. The molecular weights of the polymers were determined by gel permeation chromatography (GPC). The molecular weights were in the range of 83-129 kDa with polydispersities in the range 1.2 – 2.5 (Table 2).

Table 1.

The starting monomer amounts (mole%) for the synthesized methacrylamide (R1-R11) and 4-vinylbenzamide-based polymers (M1-M7).

Polymer

Monomers (mole%)
Dansyl Alcohol Inhibitor Asp Lys Ala
R1 10 80 10 - - -
R2 10 90 - - - -
R3 10 80 - - 10 -
R4 10 80 - 10 - -
R5 10 70 - 10 10 -
R6 10 60 10 10 10 -
R7 10 70 10 10 - -
R8 10 70 10 - 10 -
R9 10 80 - - - 10
R10 10 70 10 - - 10
R11 10 50 20 10 10 -
M1 10 80 - - 10 -
M2 10 70 10 - 10 -
M3 10 80 - 10 - -
M4 10 70 10 10 - -
M5 18 45 19 9 9 -
M6 12 64 - 12 12 -
M7 11 78 - - - 11

Table 2.

The weight average (Mw) and number average (Mn) molecular weights, polydispersities (P.I.) of the polymers R1R11, M1M7 and the concentrations used during the titration experiments with MMP isozymes.

Polymers Mw Mn P.I. Conc. used (nM)
R1 128,920 66,623 1.93 27
R2 107,291 43,945 2.44 34
R3 99,486 50,436 1.97 31
R4 119,800 52,727 2.27 28
R5 96,232 37,139 2.59 32
R6 94,514 52,959 1.78 34
R7 116,450 47,670 2.44 26
R8 93,405 47,258 1.98 36
R9 117,010 76,187 1.54 27
R10 106,802 67,273 1.59 30
R11 117,191 64,577 1.81 31
M1 106,622 66,942 1.59 29
M2 128,790 104,510 1.23 24
M3 83,618 40,895 2.04 36
M4 115,498 72,963 1.58 26
M5 114,428 78,161 1.46 27
M6 89,801 37,978 2.36 34
M7 127,656 77,145 1.65 24

To study the interactions of the synthesized polymers with the MMP isozymes, nanomolar solutions of the polymers (25 – 35 nM in 30 mM phosphate buffer, pH = 7.4, Table 1) were prepared and the MMP isozymes were added to make 200 nM of the final enzyme concentration (details are provided in Supplementary Material). The changes in the emission spectra of the polymer incorporated dansyl group were recorded in the region 350–750 nm (λex = 325 nm; Figure 1 and Supplementary Material). The emission intensity was found to decrease in the presence of added enzymes. This possibly reflects that the polymer-incorporated dansyl groups are experiencing more hydrophilic microenvironments in the presence of recombinant enzymes.20 We observed that the relative decrease in emission intensity (541 nm for polymethacrylamide polymers R1R11 and 510 nm for polyvinylbenzamide polymers M1M7) depends on the polymer used and the MMP isozyme tested. The ratios of the fluorescence emission intensities (at 541 nm and 510 nm) in the absence and in the presence of the MMP isozymes were calculated and subjected to statistical analyses to determine if they are significantly different.

Figure 1.

Figure 1

Fluorescence emission spectra of the polymer R11 (31 nM in 30 mM phosphate buffer, pH = 7.4, λex = 325 nm, black trace) in presence of 200 nM of recombinant human MMP-7 (red trace), MMP-9 (blue trace) and MMP-10 (green trace).

The primary objective of the statistical analysis was to determine whether (and to what extent) each of the polymer selectively interacts with MMP-9 isozyme. Because each of the random copolymer groups (methacrylamide and 4-vinylbenzamide, see Table 1) is fundamentally different in structure, a decision was made to analyze each group separately. A common approach to identify these relationships is linear discriminat analysis.16,17 However, the large number of polymers (11 in the methacrylamide random copolymer group and 7 in the 4-vinylbenzamide group, including one control for each group) relative to the small number of replications (6) for each enzyme-MMP pair made this approach infeasible.18 A commonly used alternative, employed in this analysis, is (binary) logistic regression.19 More specifically, each of the 18x1 data matrices containing the fluorescence intensities for a given polymer (6 replications and 3 MMPs per polymer) were “stacked” or “blocked” together to form a larger (198x1 for the methacrylamide random copolymer group and 144x1 in the 4-vinylbenzamide group) vector of fluorescence intensity readings (11 polymers with 18 observations per polymer for the methacrylamide group and 7 polymers with 18 observations for the 4-vinylbenzamide group, respectively).19 Additional columns in the data matrix were appended by creating a series of binary variables that identify each polymer, and these binary indicator variables were subsequently interacted with the fluorescence data to create a fully interacted data matrix (198x22 and 144x16 for each copolymer group, respectively). Lastly, three columns of binary variables were appended, where each new column identified a particular MMP (-7, -9 or -10). The full data matrix are provided in the Supplementary Material accompanying this manuscript.

The value of this approach is that it allows for the estimation of a fully interacted logit model of the following form:

P(MMPik=1D,F)=j=1JDij(βj+γjFij)P(MMPik=0D,F)=1P(MMPik=1D,F) (1)

where: i indexes each observation; P() denotes the cumulative logistic distribution; D is a binary indicator of each (j = 1,…,J) polymer, k denotes each isozyme (MMP-7, -9, and -10), F is the fluorescense of each isozyme; J denotes the number of polymers (11 and 7, respectively) and β, γ are parameter estimates. While this is estimated as single maximum likelihood estimation, the stacked data matrix allows separate intercept and slope estimates for each polymer included in the regression. That is, each of the polymer-specific response functions in a given group is “stacked” and estimated together to preserve adequate degrees of freedom to run the regression. As noted earlier, equation 1 is estimate twice, once for each random copolymer group.

Because the goal of the analysis was to indentify which polymers selectively interacts with MMP-9, equation (1) was estimated as a binary logit model, where the dependent variable takes a value of one for a MMP-9 isozyme, and zero if the isozyme is in the remaining categories (MMP-7, -10). This ensures a parsimonious estimation procedure without being forced to estimate equation (1) multiple times for each isozyme-copolymer grouping (MMP-9 versus MMP-7, MMP-9 versus MMP-10, etc.). Additionally, because each polymer has a separate response function with two parameter estimates (a slope and an intercept), results are presented using an odds ratio (with accompanying 95% profile confidence intervals) capturing the joint effects of these intercept and slope parameters for a given polymer on the MMP-9 isozyme. Values greater than unity (and whose confidence intervals do not contain a value of one) indicate that the polymer significantly predicts or identifies the given MMP relative to its alternatives.

Table 2 identifies those polymers whose odds ratios are significantly greater than unity. This statistical analysis revealed that it is possible to design polymers that are able to selectively interact with isozymes within the MMP family. In particular, note that polymer R11 uniquely and significantly interacts with the MMP-9 isozyme in the methacrylamide copolymer group. Polymer M5 uniquely and significantly interacts with MMP-9 among the 4-vinylbenzamide copolymer group.

Both of R11 and M5 polymers contain the aspartic- and the lysine monomers (10 mol% each) and 20 mol% of the inhibitor monomer. These two polymers also contain the least amounts of the alcohol monomers. Decreasing the amount of the inhibitor monomer to 10 mol% (i.e., polymers R6), omitting any charged monomers (polymers R8, M2 and M4) or the inhibitor monomer from the polymers (i.e., R5, M6) led to the loss of selective interactions of the polymers with MMP-9 (Supplementary Material, Table S3). Reducing the amount of inhibitor monomer (to 10 mol%) (i.e., polymer R6) or incorporation of more hydrophobic alanine-based monomer in the polymer (i.e., R10 and M7) also had negative effect on the selective interactions with MMP-9 (Supplementary Material, Table S3). We also observed that the polymers R11 and M5 (100 nM each) are effective in inhibiting the activity of the enzyme MMP-9 (Supplementary Material). Although we did not systematically vary the steric effects in the monomers, these observations suggest that possibly the inhibitor on the polymers is interacting with the active site of MMP-9 and the charged amino acids are forming additional interactions with the amino acid residues on the surface of the enzyme. Incorporation of hydrophobic monomers was detrimental to the selectivity of interactions with MMP-9. However, increasing the amount of inhibitor monomer to 30 mol% in the polymers did not improve the selective binding to MMP-9 (data not shown). We do not have an explanation for this observation yet.

Next we proceeded to determine if the selective interactions of the polymers R11 and M5 are maintained in a complex mixture of proteins. The fluorescence emission from the polymer-incorporated dansyl group (λex = 325 nm) was found to increase and blue-shift (about 100 nm; Figure 2) in the presence of dilute (less than 5% by volume) human serum in phosphate buffer (pH = 7.4). When this dilute human serum contained 200 nM of MMP-9 (levels of this enzyme in bronchial lavage fluid from lung cancer patients13), the emission intensity was substantially increased and blue-shifted (Figure 2, blue trace). The same trends were observed when the human serum contained either 200 nM MMP-7 (Figure 2, olive trace) or 200 nM MMP-10 (Figure 2, magenta trace). This indicates that the polymer-incorporated dansyl fluorophore was experiencing a more hydrophobic microenvironment in the presence of dilute human serum and the MMPs.20 We note that with the recombinant MMPs in buffer, the reverse was observed, i.e., the emission intensities decreased in the presence of added enzymes. This may indicate that the conformations of the polymers change substantially when the buffer contains small amounts of human serum. Clearly, the emission intensity in the presence of MMP-9 was more pronounced in the presence of MMP-9 compared to MMP-7 and -10. Increasing the amount of human serum to more than 5% (by volume) led to the loss of the selective enhancements of the polymer emission intensity in the presence of MMP-9 (data not shown).

Figure 2.

Figure 2

The fluorescence emission spectra of polymer R11 (50 nM) in phosphate buffer (30 mM, pH = 7.4, λex = 325 nm; black trace) was found to increase and blue-shift in the presence of dilute (2% by volume) human serum (red trace). The emission intensity changes were more pronounced when the dilute serum contained 200 nM MMP-9 (blue trace) compared to 200 nM MMP-7 (olive trace) or 200 nM MMP-10 (magenta trace).

In conclusion, we have synthesized flexible, water-soluble polymers containing charges and a weak inhibitor for the MMPs. Two of these polymers demonstrated selective interactions to the isozyme MMP-9 compared to MMP-7 and -10, even in a complex mixture of proteins (e.g., dilute human serum). We anticipate that by incorporating more potent and selective MMP inhibitors in the polymer and by optimizing the polymer structures, the selectivity of the interactions with MMP-9 can be further enhanced and maintained in more concentrated human serum samples. These studies are currently in progress and the results will be reported in the future.

Supplementary Material

01

Table 3.

Estimates and p-values from the logit regression analyses.

Methacrylamide-based Polymer 4-Vinylbenzamide-based polymer
Polymers R11 M5
Intercept 43.644 101.8
Intercept p-value 0.017 0.025
Slope −32.235 −85.875
Slope p-value 0.016 0.026
Odds Ratio (OR) 187.598 > 999.999
95% OR Lower Confidence Interval Limit 1.347 15.387
95% OR Upper Confidence Interval Limit > 999.999 > 999.999

Acknowledgments

This research was supported by NIH grants 1R01 CA 113746, 1R01 CA 132034 to SM and DKS and NSF grant DMR 1005011 to SM.

Footnotes

Supplementary Material

Experimental details of the syntheses of the monomers and the polymers; details of the fluorescence experiments and detailed results of the statistical analysis.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References and notes

  • 1.Wenck K, Koch S, Renner C, Sun W, Schrader T. J Am Chem Soc. 2007;129:16015. doi: 10.1021/ja075507p. [DOI] [PubMed] [Google Scholar]
  • 2.Renner C, Piehler J, Schrader T. J Am Chem Soc. 2006;128:620. doi: 10.1021/ja0560229. [DOI] [PubMed] [Google Scholar]
  • 3.Schrader T, Koch S. Mol BioSyst. 2007;3:241. doi: 10.1039/b614103j. [DOI] [PubMed] [Google Scholar]
  • 4.Fisher JF, Mobashari S. Methods Mol Biol. 2010;622:471. doi: 10.1007/978-1-60327-299-5_27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bellayr IH, Mu X, Li Y. Future Med Chem. 2009;1:1095. doi: 10.4155/fmc.09.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Egebald M, Werb Z. Nature Reviews Cancer. 2002;2:161. doi: 10.1038/nrc745. [DOI] [PubMed] [Google Scholar]
  • 7.Overall CM, Lopex-Otin C. Nature Reviews Cancer. 2002;2:657. doi: 10.1038/nrc884. [DOI] [PubMed] [Google Scholar]
  • 8.Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ESJM. Oncology Hematology. 2004;50:87. doi: 10.1016/j.critrevonc.2003.09.001. [DOI] [PubMed] [Google Scholar]
  • 9.Chang YH, Lin IL, Tsay GJ, Yang SC, Yang TP, Ho KT, Hsu TC, Shiau MY. Clin Biochem. 2008;41:955. doi: 10.1016/j.clinbiochem.2008.04.012. [DOI] [PubMed] [Google Scholar]
  • 10.Yong VW, Zabad RK, Agarwal S. Journal of the Neurological Sciences. 2007;259:79. doi: 10.1016/j.jns.2006.11.021. [DOI] [PubMed] [Google Scholar]
  • 11.Kessenbrock K, Plaks V, Werb Z. Cell. 2010;141:52. doi: 10.1016/j.cell.2010.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Paczek L, Michalska W, Bartlomiejczyk I. Age and Aging. 2008;37:318. doi: 10.1093/ageing/afn039. [DOI] [PubMed] [Google Scholar]
  • 13.Hurst NG, Stocken DD, Keh C, Wakelam MJO, Ismail T. Br J Cancer. 2007;97:971. doi: 10.1038/sj.bjc.6603958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Verma RP, Hansch C. Bioorg Med Chem. 2007;15:2223. doi: 10.1016/j.bmc.2007.01.011. [DOI] [PubMed] [Google Scholar]
  • 15.Banerjee AL, Tobwala S, Haldar MK, Swanson M, Roy BC, Mallik S, Srivastava DK. Chem Commun. 2005;20:2549. doi: 10.1039/b501780g. [DOI] [PubMed] [Google Scholar]
  • 16.Greene N, Shimizu K. J Am Chem Soc. 2005;127:5695. doi: 10.1021/ja0468022. [DOI] [PubMed] [Google Scholar]
  • 17.Nelson T, O’Sullivan C, Greene N, Maynor M, Lavigne J. J Am Chem Soc. 2006;128:5640. doi: 10.1021/ja060589n. [DOI] [PubMed] [Google Scholar]
  • 18.Hair J, Anderson R, Tatham R, Black W. Multivariate Data Analysis. 5. Prentice Hall; Upper Saddle River, NJ: 1998. [Google Scholar]
  • 19.Johnson R, Wichern D. Applied Multivariate Data Analysis. 5. Prentice Hall; Upper Saddle River, NJ: 2002. [Google Scholar]
  • 20.Banerjee J, Haldar MK, Manokaran S, Mallik S, Srivastava DK. Chem Commun. 2007;26:2723. doi: 10.1039/b701421j. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

01

RESOURCES